A broad representation of associates and the entire Biosim team visited last Wednesday, April 5, the biosimilar medicine production plant of the company mAbxience, located in León.
The day began with a warm reception by the mAbxience team led by its general manager, Emmanuelle Lepine, the director of Marketing and Public Affairs, Naouel Zouaghi, and the director of this production plant, Luisa Amoedo.
Next, the attendees were divided into two groups, to give the option of following the visit in both English and Spanish. The people in charge of the plant guided the group through the facilities, informing them of the processes that are carried out in said plant, in the R&D, quality control and production laboratories, always respecting the most rigorous sanitary standards of good practices. manufacturing and laboratory work (GMP and GLP). In fact, the plant was designed by its own workers so that visitors could view all the facilities and processes that are carried out on site through corridors equipped with large windows that surround the production rooms, ensuring thus the integrity of the biosimilar manufacturing process.
Finally, the groups met in the main hall of mAbxience where they had the opportunity to watch a video on the evolution of the plant presented by Lepine and Amoedo.
The plant, with more than 5.500 square meters, is one of the largest facilities in Europe with the innovative Single-Use technology, which uses single-use materials in most of its processes, from thawing cell banks to their purification and formulation of the final product, going through the cultivation and preparation of all the necessary media and solutions. It has been in operation since 2015.
With this innovative single-use bioreactor technology, demanding quality control is facilitated and production lines are optimized, minimizing any possibility of cross-contamination throughout the processes. In addition, it is an efficient and environmentally friendly technology. For example, it reduces the consumption of water and cleaning agents by more than 80%.
mAbxience is a company founded in Europe in 2009, integrated into the Chemo pharmaceutical group, and which has a broad presence in the main global pharmaceutical markets. The León plant is one of the main world references in the production of biosimilars, and an exponent of the innovation processes behind the production of these medicines. mAbxience currently has two biosimilars developed and on the market, and four more in the development phase.
